ArticleLeukemia2017
Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.Leukemia · 2021Trial
- Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.Leukemia · 2026Article
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.Blood · 2025Review
- Assessing a decade of leukaemia-related premature mortality costs: impact on productivity loss in Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML.Bone marrow transplantation · 2025Article
- Relationship Between Age, Conditioning Intensity, and Outcome After Allografting in Adults Age ≥60 Years with AML.Research square · 2024Article
- Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia.The Journal of clinical investigation · 2024Article
- How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?Blood cancer journal · 2024Article
- Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: A real-world, population-based longitudinal cohort study.PloS one · 2024Article
- TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2023Review
- Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia.Cell death discovery · 2022Article
- Socioeconomic cost of AML in Sweden-A population-based study using multiple nation-wide registers.EJHaem · 2021Article
- Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.Leukemia & lymphoma · 2021Article
- Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia.Frontiers in oncology · 2021Review
- Article
- Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation.Clinical lymphoma, myeloma & leukemia · 2020Article
- Acute myeloid leukemia in very old patients.Haematologica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.